Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Christopher T Su, Emily Nizialek, Jacob E Berchuck, Panagiotis J. Vlachostergios, Ryan Ashkar, Alexandra Sokolova, Pedro C. Barata, Rahul Raj Aggarwal, Heather McClure, Nellie Nafissi, Alan Haruo Bryce, A. Oliver Sartor, Heather H. Cheng, Nabil Adra, Cora N. Sternberg, Mary-Ellen Taplin, Marcin Cieslik, Emmanuel S. Antonarakis, Ajjai Shivaram Alva
Institutions: U-M Rogel Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Dana-Farber Cancer Institute, Weill Cornell Medicine, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Washington, Tulane University, University of California, San Francisco, Mayo Clinic Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3165933148